Accelerate to discover
Technologies
Type of the news
Brands
Low-Cost Small Molecules to Replace bFGF
Low-Cost Small Molecules to Replace bFGF, Enabling Stable and Scalable Cell Growth Benefitting R&D and Industrial Application
2026-02-04
RareCyte Spatial Biology – Immunofluorescence imaging workshop at Masaryk University, Brno
Join ACCELA and RareCyte for this special Spatial Biology - Immunofluorescence imaging workshop at Masaryk University, CAMPUS Bohunice, Meeting room in E24 (Biologypark), Studentská 812/6, Brno, Czech Republic. Monday, February 9, 2026, 9 AM.
2026-01-30
Genotype-Specific Macrophage Programs in the NSCLC Microenvironment
Understanding cell-cell interactions within the tumor-immune microenvironment is crucial for advancing cancer therapies. Macrophages show highly variable roles in tumor progression and response, yet the drivers of this complexity remain unclear.
2025-11-26
Preclinical Development for Therapy of Hard-to-Treat PD-L1-Positive Solid Tumors
They developed MDG1015 — CD8⁺ TCR-T cells armored with a PD1-41BB costimulatory switch protein (CSP) that converts PD-L1–mediated inhibition into activation. In vitro, they selectively kill PD-L1⁺ tumor cells while sparing non-target cells.
2025-11-17
Webinar recording: Unleashing the Power of Single Cell Multi-Omics, Cell Therapy – with Beacon Discovery
Join us for an exclusive webinar in collaboration with Accela exploring the Beacon platform and discover how cutting-edge single-cell technology is accelerating the discovery and development of novel therapeutics.
2025-10-10
Growing Mature Biofilms for Antimicrobial Screening, Host-pathogen Interactions, and Adhesion
We present the BioFlux shear flow system, a microfluidic flow cell array that enables the growth of biofilms in precisely controlled conditions, including shear stress, temperature, and environmental gas.
2025-06-18
Direct delivery of plasmin using clot-anchoring thrombin-responsive nanoparticles
The targeted fibrinolytic efficacy of the plasmin-loaded CTNPs was then evaluated under flow using the Bioflux microfluidic device.
2026-01-28
Perfusion: The Beating Heart of Single-Cell Biology and Cancer Immunotherapy
Single-cell biology has transformed our ability to uncover cellular diversity and dynamic behavior within complex tissues that are otherwise masked in population-level analyses.
2025-11-24
Introducing EOS6: High content – live cell analysis inside your incubator
Built to support multiple users and applications, the EOS6 can run up to six microplates in parallel, flask, dishes, slides… Users can schedule experiments at different image acquisition frequencies and magnifications in parallel.
2025-10-24
Applications: Phase Contrast and Fluorescence Microscopy
Phase contrast and fluorescence microscopy reveals structural and molecular details in cells. Lumascope microscopes are ideally suited for research that requires both, for example this cancer-related study.
2025-08-18
IsoSpark in HIV research: quantitation of proteins in the culture supernatants.
Exciting example of use 22-plex antibody with the IsoPlexis Human Adaptive Immune Panel (Bruker Cellular Analysis) in HIV research.
2025-06-12
Functional, Fast, and Unbiased TCR Discovery with Bruker’s Optofluidic Platform
Identifying antigen specific T-cell receptors (TCRs) is critical for advancing TCR-T therapies, vaccines, and infectious disease research. Yet, traditional peptide-MHC tetramer/dextramer sorting only tells part of the story.
2026-01-23
Advances in Biofilm Research: How the Experts are Overcoming Obstacles
There are plenty of areas of interest when working with biofilms. In this article we focus on two major ones: biofilm drug resistance and antibiofilm drug development and the approach one can take in research.
2025-11-19
Refining Biomedical Research Beyond Animal Models
What the Pivot to Human-Based Technologies Means for Science and How 3D Cellular Constructs like Organoids Are Part of the Solution.
2025-10-13
Incorporation of SARS-CoV-2 spike NTD to RBD protein vaccine improves immunity against viral variant
By fusing the spike protein's terminal domain (NTD) with its receptor-binding domain (RBD), researchers have engineered a protein vaccine that significantly amplifies both T-cell responses and antibody breadth.
2025-06-25
BioFocus newsletter
Register to receive Brand new technology development, Important product updates, Interesting scientific events and more!
Technologies